Kyverna Therapeutics, Inc. - Common Stock (KYTX)

Today, Dec. 15, 2025, stocks dipped as growth shares faltered and traders assessed trade risk alongside Fed commentary.

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

In the KYSA-8 trial, a single infusion of miv-cel delivered sustained improvements across both primary and secondary measures of Stiff Person Syndrome.

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

William Blair starts Kyverna coverage with Outperform, citing KYV-101's potential as the first FDA-approved CAR-T therapy in autoimmune disease.

HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.

As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.

KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune disease patients but faces challenges in cost and manufacturing.

Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. Here's a look at the details: